Dear Reader,

Last year I ran for Mayor of New York City.

And lost to a 34-year-old Democratic Socialist.

Now I’m convinced what’s starting in New York will spread across America.

Just for starters:

• The new mayor wants to spend $70 million of taxpayer money just to study whether government-run grocery stores are a good idea.
• He’s threatening a 9.5% property tax hike on every homeowner in the city.
• And he wants to raise taxes on every corporation and high earner.

This isn’t just a New York story. Nearly 40% of Americans now have a “positive” view of socialism.

But what nobody’s talking about is WHY this is happening… and where it’s all headed.

I have my MBA from Harvard and spend my time in correspondence with billionaires like Warren Buffett and Bill Ackman. I’ve spent 30 years on Wall Street. And there’s a specific term for what’s unfolding in America right now… one that points to an economic event unlike anything we’ve seen in over 100 years.

I’m not running for office again. But if you care about your wealth, your family, and your future, you need to understand what’s really coming.

I’ve put together a free analysis explaining exactly what I see, and the specific steps I recommend you take with your money today.

I strongly encourage you to check it out here.

Regards,

Whitney Tilson
Editor, Stansberry Investment Advisory
Former Hedge Fund Manager
Co-Founder, Teach for America
Harvard MBA

P.S. What’s happening today will reset the financial system in a way most of us can’t imagine. If I’m even half right, it’s going to have a huge impact on your money and your future. Get the details here…

---

Further Reading from MarketBeat.com

3 Biotech Stocks That Could Benefit from the Patent Cliff

Authored by Chris Markoch. Date Posted: 4/27/2026. 

Key Points

• Biotech M&A activity is accelerating ahead of a projected $300 billion patent cliff, creating new opportunities in smaller, innovative companies.
• Gene editing leaders like CRISPR Therapeutics, Intellia Therapeutics, and Beam Therapeutics offer differentiated platforms that could attract acquisition interest.
• Investors willing to take on higher risk may find outsized upside in biotech stocks developing one-time curative therapies for chronic diseases.
• Special Report: Elon’s “Hidden” Company

Biotechnology stocks have seen a spike in merger and acquisition (M&A) activity. In March 2026 alone, there were 10 deals valued at approximately $31.5 billion.

A key driver of this activity is the upcoming patent cliff — the period when a drug loses exclusivity and faces biosimilar competition. Analysts are forecasting the industry will confront roughly a $300 billion patent cliff by 2030.

Ticker Revealed: Pre-IPO Access to “Next Elon Musk” Company (Ad)

We’ve found The Next Elon Musk… and what we believe to be the next Tesla. 

It’s already racked up $26 billion in government contracts.

Peter Thiel just bet $1 Billion on it.👉 Unlock the ticker now and get it completely free.

Two large-cap biopharma companies with best-selling drugs approaching the cliff are Merck & Co. (NYSE: MRK) with its blockbuster Keytruda and Bristol Myers Squibb (NYSE: BMY) with Eliquis. These are quality names that offer investors the relative safety of strong balance sheets and dividends.

That dynamic creates an opportunity for investors with a higher risk tolerance: small- and mid-cap companies that could become acquisition targets. Many of these firms specialize in therapeutics that could shift the biotech paradigm from chronic management to one-time cures.

Acquirable Assets: Which Biotechs Deserve a Higher Floor

Sectors often move in tandem, but right now the biotech companies with the most upside are those with acquirable assets. Investors should look for three things:

1. The underlying science is sufficiently differentiated that a large-cap competitor can’t quickly replicate it.
2. The company owns its intellectual property.
3. The indication is large enough to meaningfully move revenue and earnings for an acquirer.

Many small-cap biotech names don’t meet every bar, which is one reason this is a challenging sector for investors. Still, there are three companies worth watching — each sits at a different point on the risk/maturity curve.

This isn’t a prediction that these firms will be acquired, but they check the three boxes above and offer the promise of potential one-time cures for chronic or untreatable diseases.

First-Mover Advantage in Gene Editing

Gene editing is a paradigm-shifting opportunity, and CRISPR Therapeutics (NASDAQ: CRSP) is an established pure play in the space. Unlike many peers, CRISPR already has a product on the market: in fact, CASGEVY delivered over $100 million in revenue in 2025, and the company says patient initiations have nearly tripled year-over-year.

CASGEVY treats sickle cell disease (SCD) and beta-thalassemia — large but relatively niche markets. A key growth vector for CRSP may be its work in cardiovascular disease: the company’s CTX310 candidate is positioned as a potential one-and-done therapy to rapidly lower triglyceride and LDL levels.

CTX310 recently reported positive Phase 1 data. That still leaves a runway to commercial approval, but the early results are encouraging.

Analysts are generally optimistic on CRSP; of the 19 analysts tracked by MarketBeat, two carry Sell ratings. Short interest is roughly 24% as of this writing. Given that mix, investors may prefer to scale into positions gradually and use dips as opportunities to add exposure.

High-Risk, High-Reward In Vivo Editing

If CRISPR Therapeutics is the most commercially mature name in the space, Intellia Therapeutics (NASDAQ: NTLA) represents the highest-stakes bet. Intellia is a pioneer of in vivo CRISPR editing — making genetic edits directly inside the body rather than ex vivo — which dramatically expands the range of diseases that gene editing can potentially treat.

Intellia’s two late-stage candidates are nexiguran ziclumeran (nex-z), developed with Regeneron for transthyretin amyloidosis (ATTR), and lonvoguran ziclumeran (lonvo-z), a wholly owned program for hereditary angioedema (HAE). Both target rare, underserved diseases where a one-time functional cure would represent a true paradigm shift from chronic management.

Key 2026 catalysts include a Phase 3 data readout for lonvo-z in HAE expected April 27, 2026, and progress reinvigorating the ATTR cardiomyopathy program after the FDA lifted its clinical hold. Either development could move the stock materially in either direction. NTLA is not for the faint of heart, but for investors who believe in the in vivo thesis, it’s the purest expression of that approach.

Precision Gene Editing’s Next Frontier

Where Intellia focuses on CRISPR-Cas9, Beam Therapeutics (NASDAQ: BEAM) is developing base editing, which acts like a molecular pencil — rewriting a single genetic letter rather than making a double-strand cut. That precision may help address safety concerns that have kept some investors on the sidelines.

Beam’s most advanced wholly owned program, BEAM-302, targets alpha-1 antitrypsin deficiency (AATD), a genetic disorder of the lungs and liver that currently has no curative therapy.

In March 2026, Beam reported positive updated Phase 1/2 data and said it plans to advance BEAM-302 into pivotal testing in the second half of the year. Its sickle cell program, risto-cel, could see a U.S. approval filing as early as late 2026.

Beam carries more early-stage risk than CRSP and faces nearer-term funding questions given its cash runway. Nevertheless, its differentiated platform and proximity to pivotal data make it a name worth monitoring for investors willing to accept that risk in exchange for the upside a successful readout or acquisition could deliver.

---

Further Reading from MarketBeat.com

Google Cloud Next 2026 Event Bets Big on AI Infrastructure

Authored by Ryan Hasson. Date Posted: 4/25/2026. 

Key Points

• Alphabet rebranded Vertex AI as the Gemini Enterprise Agent Platform, positioning it as a unified control plane for enterprise AI agent deployment.
• The company unveiled eighth-generation dual-chip TPUs and the Virgo Network, demonstrating how it is deploying its $175 billion to $185 billion capex commitment.
• Workspace Intelligence reached general availability, and a new migration tool lets organizations switch from Microsoft 365 up to five times faster than before.
• Special Report: Elon’s “Hidden” Company

Google Cloud Next 2026 wrapped up its opening two days in Las Vegas with one of the most ambitious and wide-ranging sets of announcements in the event’s history.

For investors watching Alphabet (NASDAQ: GOOGL), the timing is significant. The stock closed on Thursday at $338.89, just 2.9% below its all-time high. With Q1 2026 earnings due April 29, the company also gave the market a detailed preview of what its $175 billion to $185 billion 2026 capital expenditure (CapEx) commitment is actually building.

Ticker Revealed: Pre-IPO Access to “Next Elon Musk” Company (Ad)

We’ve found The Next Elon Musk… and what we believe to be the next Tesla. 

It’s already racked up $26 billion in government contracts.

Peter Thiel just bet $1 Billion on it.👉 Unlock the ticker now and get it completely free.

The answer is a full-stack AI enterprise platform, and the announcements from Cloud Next make that vision more concrete. Here are some of the event’s biggest announcements and takeaways so far.

The 8th-Generation TPU: 2 Chips for the Agentic Era

The headline infrastructure announcement was the unveiling of Google’s eighth-generation TPUs, a dual-chip architecture designed specifically for what the company calls the agentic era. The TPU 8t is optimized for accelerated model training, while the TPU 8i targets cost-effective inference at near-zero latency. As AI deployments shift from training large models to running them continuously at enterprise scale, inference cost and latency become the primary competitive variables. Google’s decision to build dedicated silicon for each workload reflects an infrastructure sophistication that’s difficult to replicate.

Alongside the TPUs, Google announced the Virgo Network, a new mega-scale data center fabric designed to underpin the AI Hypercomputer—its term for clusters of thousands of interconnected chips operating as a single system. Managed Lustre storage, delivering 10 terabytes per second of throughput, rounds out the infrastructure stack. Together, these announcements indicate that the $175 billion to $185 billion CapEx commitment is being deployed with precision, not just scale.

Vertex AI Is Now the Gemini Enterprise Agent Platform

Perhaps the most strategically significant announcement was the rebranding of Vertex AI as the Gemini Enterprise Agent Platform. The rebrand signals a fundamental shift in how Google is positioning its cloud business. This is no longer a collection of machine-learning tools; it is a unified, end-to-end control plane for building, deploying, securing, and orchestrating AI agents at enterprise scale.

Google Cloud CEO Thomas Kurian framed the competitive argument directly: while rivals are handing customers pieces, Google is offering the whole platform. It is a bold claim, but the logic has merit. Google is the only major hyperscaler that controls custom silicon, frontier AI models, a cloud platform, and an enterprise productivity suite with billions of users. The Gemini Enterprise Agent Platform is the layer that attempts to unify all four into a single operating system for the AI enterprise.

The platform includes a new Agent Designer for building schedule- and trigger-based agents, long-running agents capable of executing complex business processes, and an inbox for managing agent activity, all integrated natively with Google Workspace.

Workspace Intelligence and the Enterprise Distribution Advantage

Workspace Intelligence reached general availability at Cloud Next, delivering, according to Google, a unified, real-time understanding across its productivity applications. The system goes beyond simple data retrieval, incorporating a dynamic understanding of semantic relationships across documents, projects, collaborators, and organizational context.

Also announced, Rapid Enterprise Migration now enables organizations to migrate from Microsoft 365 to Google Workspace up to five times faster than before — a direct competitive thrust against Microsoft’s (NASDAQ: MSFT) dominance in enterprise productivity.

The scale of Google’s distribution through Workspace is often underappreciated in discussions of the AI cloud race. Three billion users across Workspace apps represent a deployment channel that neither Amazon’s (NASDAQ: AMZN) AWS nor Microsoft’s Azure can match through productivity software alone.

The Numbers Behind the Conference

CEO Sundar Pichai revealed that 75% of all new code written at Google is now AI-generated, up from approximately 25% just a year ago.

Google’s first-party models are now processing 16 billion tokens per minute via direct customer APIs, up from 10 billion in the prior quarter. Google also committed $750 million to a partner fund to accelerate the adoption of agentic AI across its 120,000-member global partner ecosystem.

Analysts maintain a consensus “Moderate Buy” rating on GOOGL, with a price target of $369.67, implying about 7% upside potential.

The Q1 earnings report on April 29 — when Google Cloud growth is expected to exceed 50% year over year — will be the next test of whether the infrastructure investment is translating into revenue at the pace the market is pricing in.

This email is a paid advertisement for Stansberry Research, a third-party advertiser of MarketBeat. Why was I sent this email message?. 

This ad is sent on behalf of Stansberry Research, 1125 N Charles St, Baltimore, MD 21201. If you would like to optout from receiving offers from Stansberry Research please click here.


If you need help with your newsletter, please don’t hesitate to email MarketBeat’s U.S. based support team at contact@marketbeat.com.

If you would no longer like to receive promotional emails from MarketBeat advertisers, you can unsubscribe or manage your mailing preferences here.

© 2006-2026 MarketBeat Media, LLC. All rights reserved.
345 N Reid Pl., Sixth Floor, Sioux Falls, South Dakota 57103-7078. United States of America..

See Also: Crash Expert: “This Looks Like 1929” → 71,048 Diversifying Here(From Masterworks Administrative Service LLC)